Dubé Marie-Pierre, de Denus Simon, Tardif Jean-Claude
Montreal Heart Institute, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada.
Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada.
Cardiovasc Drugs Ther. 2016 Feb;30(1):59-64. doi: 10.1007/s10557-015-6637-y.
Investment in cardiovascular drug development is on the decline as large cardiovascular outcomes trials require considerable investments in time, efforts and financial resources. Pharmacogenomics has the potential to help revive the cardiovascular drug development pipeline by providing new and better drug targets at an earlier stage and by enabling more efficient outcomes trials. This article will review some of the recent developments highlighting the value of pharmacogenomics for drug development. We discuss how genetic biomarkers can enable the conduct of more efficient clinical outcomes trials by enriching patient populations for good responders to the medication. In addition, we assess past drug development programs which support the added value of selecting drug targets that have established genetic evidence supporting the targeted mechanism of disease. Finally, we discuss how pharmacogenomics can provide valuable evidence linking a drug target to clinically relevant outcomes, enabling novel drug discovery and drug repositioning opportunities.
由于大型心血管结局试验需要在时间、精力和财力上投入巨大，心血管药物研发的投资正在下降。药物基因组学有潜力通过在早期提供新的、更好的药物靶点，并开展更高效的结局试验，来帮助重振心血管药物研发流程。本文将回顾一些近期的进展，突出药物基因组学在药物研发中的价值。我们将讨论基因生物标志物如何通过使患者群体富集对药物有良好反应者，从而开展更高效的临床结局试验。此外，我们评估了过去的药物研发项目，这些项目支持选择有确凿遗传证据支持疾病靶向机制的药物靶点所带来的附加价值。最后，我们讨论药物基因组学如何能够提供有价值的证据，将药物靶点与临床相关结局联系起来，从而带来新的药物发现和药物重新定位的机会。
